Natalizumab Use in Pediatric Multiple Sclerosis
نویسندگان
چکیده
منابع مشابه
Natalizumab use in pediatric multiple sclerosis.
BACKGROUND Natalizumab, a humanized monoclonal antibody raised against alpha4 integrins, is approved for treatment of active relapsing-remitting multiple sclerosis (RRMS) in adult patients. OBJECTIVE To determine the safety, effectiveness, and tolerability of natalizumab use in pediatric patients with MS. DESIGN Case report. SETTING Center for MS in childhood and adolescents, Göttingen, G...
متن کاملNatalizumab in pediatric multiple sclerosis patients.
Pediatric multiple sclerosis (MS) comprises 2-5% of all cases of MS. Although first-line disease-modifying therapy (DMT) including interferons and glatiramer acetate appear to be well tolerated in this population, recent work has suggested that a growing number of children suffer from disease which is resistant to treatment with these therapies. Natalizumab is a therapy which, although associat...
متن کاملUse of natalizumab in multiple sclerosis patients.
Natalizumab is a monoclonal antibody indicated in Canada as monotherapy for the treatment of multiple sclerosis (MS) patients with relapsing-remitting disease. The phase III clinical trial of natalizumab monotherapy demonstrated substantial improvements in clinical and magnetic resonance imaging (MRI) parameters in patients with relapsing-remitting MS, with statistically significant reductions ...
متن کاملThe use of natalizumab for multiple sclerosis
Natalizumab is a monoclonal antibody that acts as an α4 integrin antagonist to prevent leukocyte trafficking into the central nervous system. It is US Food and Drug Administration (FDA) approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Natalizumab demonstrated high efficacy in Phase III trials by reducing the annualized relapse rate, preventing multiple sclerosis (MS)...
متن کامل[Natalizumab treatment in multiple sclerosis].
Multiple sclerosis is a neurodegenerative and inflammatory immune disorder in the central nervous system (CNS). Most patients show relapse-remitting clinical course. Some disease modifying medications for preventing the relapses including natalizumab (NTZ) are approved in Japan. Natalizumab (NTZ), a monoclonal antibody against α4 integrin present on the surface of lymphocytes, inhibits the bind...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Neurology
سال: 2008
ISSN: 0003-9942
DOI: 10.1001/archneur.65.12.1655